Kisspeptin-10: A Hypothalamic Decapeptide Regulator of the Reproductive Axis

Research summary. Kisspeptin-10 is a C-terminal decapeptide fragment of the kisspeptin family of peptides encoded by the KISS1 gene. It is the shortest fragment that retains full agonist activity at the kisspeptin receptor (KISS1R, formerly GPR54) and has become a foundational research tool for studying the upstream control of gonadotropin-releasing hormone (GnRH) secretion, energy-balance / reproduction crosstalk, metastasis suppression biology, and limbic responses to reproductive signalling.

Molecular profile

• Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ (YNWNSFGLRF-NH₂)
• Molecular formula: C₆₃H₈₃N₁₇O₁₄
• Molecular weight: ~1302.4 g/mol
• Family: RFamide-related peptides; C-terminal -Arg-Phe-NH₂ motif is critical for KISS1R binding
• Parent peptide: Kisspeptin-54 (metastin); kisspeptin-10 is the shortest fully active fragment

Mechanism of action

Kisspeptin-10 binds and activates KISS1R, a Gαq-coupled GPCR expressed at high density on hypothalamic GnRH neurons. Receptor engagement produces:

• GnRH release from hypothalamic neurons via PLCβ–IP3–calcium signalling
• Downstream LH and FSH secretion from the anterior pituitary as a consequence of GnRH stimulation
• Modulation of GnRH pulse generator activity — kisspeptin is the principal upstream stimulus that organises pulsatile GnRH release
• Direct action in peripheral tissues including adipose, kidney, and vasculature, where KISS1R is also expressed at lower density
• Anti-metastatic signalling in tumour cells, producing reduced cell motility and invasion in KISS1R-expressing cancer lines

The peptide is the proximal trigger for puberty onset; loss-of-function mutations in KISS1R in humans produce normosmic hypogonadotropic hypogonadism, establishing the kisspeptin–KISS1R axis as a non-redundant gatekeeper of the reproductive cascade.

Preclinical and translational research highlights

Discovery of KISS1R as the kisspeptin receptor. The pivotal genetic and pharmacological identification of GPR54 (KISS1R) as the kisspeptin receptor and its central role in puberty was reported in 2003, including human loss-of-function mutations producing absent puberty [1].

LH and testosterone responses in men. Clinical investigation has reported that intravenous administration of kisspeptin-10 in healthy men produces rapid, dose-dependent increases in serum LH followed by testosterone, consistent with potent stimulation of the GnRH pulse generator [2]. Sex-specific effects have been described, with female responses being more dependent on cycle phase.

Pulse-generator modulation. Studies in primate and rodent models have characterised kisspeptin neurons in the arcuate nucleus (the so-called KNDy neurons co-expressing kisspeptin, neurokinin B, and dynorphin) as the anatomical substrate of the GnRH pulse generator. Kisspeptin-10 administration has been used to map these circuits.

Energy-balance crosstalk. Genetic deletion of Kiss1r in rodent models produces increased adiposity and reduced energy expenditure, with KISS1R expression confirmed in white and brown adipose tissue. Reciprocally, kisspeptin neurons are sensitive to leptin and other energy-status signals, providing a molecular substrate for the long-recognised coupling between nutritional status and reproductive function.

Metastasis-suppression biology. KISS1 was originally cloned as a metastasis-suppressor gene in melanoma. Subsequent work in multiple tumour models has reported reduced cell migration and invasion following kisspeptin exposure. Expression patterns of KISS1/KISS1R are altered in breast, bladder, GI, prostate, pancreatic, ovarian, and thyroid cancer, though the directionality and clinical relevance remain heterogeneous.

Limbic and affective responses. Functional MRI studies have reported that intravenous kisspeptin in healthy men enhances limbic activity in response to sexual and couple-bonding visual stimuli, with concurrent changes in self-reported mood, consistent with central effects beyond the strictly hypothalamic.

Current research status

Kisspeptin-10 remains an investigational research peptide with active translational programmes in reproductive endocrinology. It is not approved as a therapeutic by major regulatory authorities. Active research domains include:

• Diagnostic kisspeptin challenge testing for hypogonadotropic hypogonadism
• Trigger of oocyte maturation in IVF as an alternative to hCG (active clinical research)
• Mechanistic studies of the GnRH pulse generator
• Reproductive–metabolic crosstalk and obesity-associated infertility
• Tumour-biology research, particularly metastasis and angiogenesis

Key takeaways for researchers

• Kisspeptin-10 is the shortest fully active C-terminal fragment of KISS1-encoded peptides and a high-affinity KISS1R agonist.
• It is the principal upstream stimulus of GnRH release and an essential gatekeeper of pubertal onset and adult reproductive function.
• Sex-specific responses are well characterised, with men showing robust LH and testosterone elevation following intravenous kisspeptin-10.
• Beyond reproduction, KISS1R signalling intersects with energy balance, vascular biology, and metastasis suppression.
• It is widely used as a research tool for mapping and probing the kisspeptin–GnRH axis.

References

1. de Roux N, Genin E, Carel J-C, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences. 2003;100(19):10972–10976.
2. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism. 2005;90(12):6609–6615.

---

This article is provided for educational and research purposes only. Kisspeptin-10 is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.